Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Position Cut by Federated Hermes Inc.

Federated Hermes Inc. lessened its position in Mineralys Therapeutics, Inc. (NASDAQ:MLYS) by 10.1% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 20,032 shares of the company’s stock after selling 2,261 shares during the period. Federated Hermes Inc.’s holdings in Mineralys Therapeutics were worth $172,000 at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. China Universal Asset Management Co. Ltd. bought a new position in Mineralys Therapeutics in the 4th quarter worth about $41,000. SG Americas Securities LLC acquired a new stake in Mineralys Therapeutics in the 4th quarter valued at approximately $87,000. Cornercap Investment Counsel Inc. bought a new stake in Mineralys Therapeutics during the 4th quarter valued at $191,000. Jump Financial LLC acquired a new position in Mineralys Therapeutics during the 3rd quarter worth $311,000. Finally, Raymond James Financial Services Advisors Inc. bought a new position in shares of Mineralys Therapeutics in the third quarter worth $386,000. 84.46% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the stock. The Goldman Sachs Group initiated coverage on shares of Mineralys Therapeutics in a research note on Tuesday, April 2nd. They set a “buy” rating and a $30.00 price objective on the stock. Lifesci Capital restated an “outperform” rating on shares of Mineralys Therapeutics in a research report on Tuesday, March 26th.

Mineralys Therapeutics Stock Performance

Shares of MLYS stock opened at $12.95 on Monday. Mineralys Therapeutics, Inc. has a 1 year low of $5.85 and a 1 year high of $17.70. The business’s fifty day moving average is $13.03 and its 200-day moving average is $10.53. The stock has a market cap of $642.71 million, a PE ratio of -6.48 and a beta of 2.05.

Mineralys Therapeutics (NASDAQ:MLYS) last announced its earnings results on Thursday, March 21st. The company reported ($0.61) earnings per share for the quarter, beating the consensus estimate of ($0.85) by $0.24. Equities research analysts predict that Mineralys Therapeutics, Inc. will post -2.44 earnings per share for the current year.

Insider Activity

In other Mineralys Therapeutics news, major shareholder Samsara Biocapital Gp, Llc bought 555,555 shares of the company’s stock in a transaction that occurred on Monday, February 12th. The shares were acquired at an average cost of $13.50 per share, for a total transaction of $7,499,992.50. Following the acquisition, the insider now directly owns 5,074,916 shares of the company’s stock, valued at $68,511,366. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders own 33.24% of the company’s stock.

About Mineralys Therapeutics

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.